Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals has informed BSE and NSE that its Board of Directors will meet on January 21, 2026. The main agenda is to consider and approve the Unaudited Financial Results for the quarter and nine months ended December 31, 2025 (Q3 FY26). The trading window for dealing in the company's securities will remain closed till January 23, 2026, in line with insider trading norms. No specific financial numbers or guidance have been disclosed in this intimation.
This is a routine pre-results announcement with no direct impact on share price. Investors should watch the actual Q3 FY26 results on January 21, 2026 for revenue, profit, and margin trends, which could drive the next stock move.